PDE5 inhibitors are also effective and safe in almost all patient groups with organic ED, including difficult-to-treat subgroups, such as individuals with diabetes, hypertension, chronic kidney disease, prostatectomy-induced ED and neurological disorders. This evidence concerns the gene PDE5A and chronic kidney disease.